Revolutionary Cell Therapy Shows Promise: Over 90% Seizure Reduction in Drug-Resistant Epilepsy Patients
Neurona Therapeutics, a clinical-stage biotherapeutics company, is developing regenerative cell therapies for the treatment of neurological disorders. They recently presented updated clinical data from their ongoing Phase I/II trial of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy (MTLE) at the American Academy of Neurology 2023 Annual Meeting. The data showed a >90% reduction […]
Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data
SAN FRANCISCO, Nov. 21, 2022 (GLOBE NEWSWIRE) — Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced that Cory R. Nicholas, Ph.D., Neurona’s president and chief executive officer, was invited to present an overview of Neurona’s regenerative cell therapy technology, proprietary manufacturing process, cell delivery system, and preclinical […]